



NATIONAL  
QUALITY FORUM

# Behavioral Health and Substance Use Spring 2018 Review Cycle

CSAC Review and Endorsement

*October 23, 2018*

# Behavioral Health and Substance Use

- The Behavioral Health and Substance Use project aims to endorse measures of accountability for improving the delivery of behavioral health and substance use services and achieving better health outcomes for the U.S. population.
- NQF's Behavioral Health and Substance Use portfolio includes 54 measures that address the following topic areas:
  - » Tobacco
  - » Alcohol and substance use
  - » Depression
  - » Medication use
  - » Care Coordination
  - » Physical health

# Behavioral Health and Substance Use

- Measures Under Review:
  - **Nine** measures under consideration
  - **Seven** maintenance measures and **two** new measures
- Topic areas:
  - *Suicide risk assessments*
  - *Medication adherence and management*
  - *Diabetes and cardiovascular screening and monitoring for individuals with schizophrenia and bipolar disorder*
  - *Concurrent use of opioids and benzodiazepines*
  - *Use of pharmacotherapy for opioid use disorder*
- No measures were submitted to the Scientific Methods Panel

# Behavioral Health and Substance Use Standing Committee Recommendations

- 0104e Adult Major Depressive Disorder (MDD): Suicide Risk Assessment (PCPI)
- 0105 Antidepressant Medication Management (AMM) (NCQA)
- 1879 Adherence to Antipsychotic Medications for Individuals with Schizophrenia (CMS/NCQA)
- 1880 Adherence to Mood Stabilizers for Individuals with Bipolar I Disorder (CMS/NCQA)
- 1932 Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD) (NCQA)
- 1933 Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC) (NCQA)
- 1934 Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD) (NCQA)
- 3389 Concurrent Use of Opioids and Benzodiazepines (COB) (PQA)
- 3400 Use of Pharmacotherapy for Opioid Use Disorder (OUD) (CMS/Mathematica Policy Research)

# Measure Evaluation Summary

	Maintenance Measures	New Measures	TOTAL Measures
Submitted	7	2	9
Measures Recommended	7	2	9
Measures Not Recommended	0	0	0
Measures Withdrawn from Consideration	0	0	0
Reasons for not recommending:	Importance – N/A Scientific Acceptability – N/A Overall – N/A	Importance – N/A Scientific Acceptability – N/A Overall – N/A	

# Overarching Issues

- Medication adherence
  - *Committee would like to see consistent language across behavioral health and substance use for all medication adherence measures.*
- NQF measure evaluation criteria changes
  - *NQF received several communications from measure developers expressing concern that the change in the subcriterion allowed for a very short window of time to respond to the new testing requirement.*
- Overall performance improvement rates
  - *Updated performance data showed little overall performance improvement despite continued variation indicating a gap in care in maintenance measures.*

# Public and NQF Member Comments Received

- 57 comments were received from 17 organizations (including nine member organizations)
- Four major themes were identified in the comments:
  - *General Comments*
  - *Feasibility/Data Collection*
  - *Expansion of Measured Population*
  - *Unintended Consequences*
- The Committee did not vote on any measures on the post-comment web meeting

# Member Expression of Support

- Four NQF members provided their expression of support
- Measures that received support:
  - ▣ *0104e Adult Major Depressive Disorder (MDD): Suicide Risk Assessment (PCPI Foundation)*
  - ▣ *0105 Antidepressant Medication Management (AMM) (NCQA)*
  - ▣ *1879 Adherence to Antipsychotic Medications for Individuals with Schizophrenia (CMS/NCQA)*
  - ▣ *1880 Adherence to Mood Stabilizers for Individuals with Bipolar I Disorder (CMS/NCQA)*
  - ▣ *1932 Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD) (NCQA)*
  - ▣ *1933 Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC) (NCQA)*
  - ▣ *1934 Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD) (NCQA)*
- Measures that received both support and nonsupport:
  - ▣ *3389 Concurrent Use of Opioids and Benzodiazepines (COB) (PQA)*
  - ▣ *3400 Use of Pharmacotherapy for Opioid Use Disorder (OUD) (CMS/Mathematica Policy Research)*



# Timeline and Next Steps

Process Step	Timeline
<b>Appeals Period</b>	October 26, 2018-November 26, 2018
<b>Adjudication of Appeals</b>	November 27, 2018-December 21, 2018
<b>Final Report</b>	Early February 2019

# Questions?

- Project page: [http://www.qualityforum.org/Behavioral Health and Substance Use.aspx](http://www.qualityforum.org/Behavioral_Health_and_Substance_Use.aspx)
- Email: [Behavioralhealth@qualityforum.org](mailto:Behavioralhealth@qualityforum.org)